Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSStandard

PIASKY

CROVALIMAB-AKKZ

Standard Dose
340MG/2ML(170MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Prescription
Summary

Approval overview PIASKY is listed in Drugs@FDA under application 761388 (BLA).

Review priority: N/A Marketing status: Prescription Active ingredient CROVALIMAB-AKKZ Form and strength INJECTABLE;INTRAVENOUS - 340MG/2ML(170MG/ML) Sponsor GENENTECH INC Submission history Latest submission status date: 2025-05-14 00:00:00.

Structured Monograph

Clinical summary

Approval overview PIASKY is listed in Drugs@FDA under application 761388 (BLA). Review priority: N/A Marketing status: Prescription Active ingredient CROVALIMAB-AKKZ Form and strength INJECTABLE;INTRAVENOUS - 340MG/2ML(170MG/ML) Sponsor GENENTECH INC Submission history Latest submission status date: 2025-05-14 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: N/A

Interaction Notes

  • No interaction notes stored yet.